Title: 1977 in science
Content: The first complete genome is sequenced - a tiny bacterium-infecting virus called Phi X 174, with just 11 genes, and a little over 5000 base pairs. ; Carl Woese and George E. Fox classify archaea as a new, separate domain of life. ; U.S. Food and Drug Administration approves LAL (Limulus amebocyte lysate) for testing drugs, products and devices that come in contact with the blood. Prior to this date, a much slower and more expensive test on rabbits has been used for this purpose. ; October 22 – Nothomyrmecia, the "dinosaur ant", is rediscovered, in Poochera, South Australia, more than 45 years after it is first described. 
Title: Alan Walton
Content:  new, university-based technologies with strong patent positions and make them the centerpiece of new companies. Companies financed by Oxford included Martek Biosciences Corporation, Geron Corporation, Exelixis, and Gene Finder, among others. In 1992, Walton, Wally Steinberg, and Craig Venter founded Human Genome Sciences (HGS), a company that bought the assets of Gene Finder and sought to use human DNA sequences to develop protein and antibody drugs. Around the same time, Walton helped Venter set up The Institute for Genome Research, a non-profit the discoveries of which were marketed by HGS. HGS went public the next year and the stock was heavily subscribed.
Title: Phase Genomics
Content:  The company was founded by Ivan Liachko and Shawn Sullivan in 2015. It was originally housed in the CoMotion biotech incubator at University of Washington before relocating to a separate facility. It develops proximity ligation kits and Hi-C sequencing technology used to analyze chromosomes, assemble genomes, understand microbial communities, and identify structural variation in the human genome associated with conditions such as cancer and infertility. The company sells proximity ligation kits, scientific services, and computational analyses.
Title: Gen-Probe
Content:  Gen-Probe was a company based in San Diego, in California, specializing in clinical diagnostics, blood screening, transplantation products and research products. The company's molecular diagnostics products were used for diagnosis of infectious diseases, blood screening, analyzing blood transfusions for immune response, testing coagulation pathways, and organ transplantation viability. Their products and services also included technology and know-how in biomedical research and drug development.
Title: Synthetic Genomics (company)
Content:  to produce biofuels on an industrial-scale using recombinant algae and other microorganisms. The company purchased an 81 acre site in Southern California's Imperial valley to produce algae fuel for their collaboration with Exxon Mobil. They also signed a collaborative agreement with New England Biolabs to Launch Gibson Assembly Master Mix Product for Synthetic and Molecular Biology Applications in 2012. In 2010, Synthetic Genomics spun off a new subsidiary, Synthetic Genomics Vaccines Inc., to develop next generation vaccines In 2014 SGI expanded into the field of organ transplantation with a collaborative agreement with United Therapeutics valued at $50M and brought in Oliver Fetzer as CEO.
Title: Human Genome Sciences
Content:  The company was founded by Alan Walton, Wally Steinberg and Craig Venter who at the time founded the non-profit TIGR to begin sequencing and submitting patents on hundreds of thousands of protein-encoding DNA fragments. In 1993 Wally Steinberg hired Bill Haseltine as the first CEO of HGS. In 2000, Haseltine said that the company 's work "speeds up biological discovery a hundredfold, easily." He talked of finding in genes "the fountain of youth" in the form of "cellular replacement" therapies. More than $2 billion in investments was raised by the company by 1999-2000. Two initial drugs failed in clinical trials, and the stock 
Title: Genome Valley
Content: Ocimum Biosolutions ; Excelra ; Makro care ; SIRO-Clinpharm ; Sipra Labs ; Alveus Pharmaceuticals ; Sandor Proteomics ; Laurus Labs ; Bio-Axis ; Clin Asia ; Clintec International ; Andronovo Labs ; Piramal Clinical ; Diacel ; Vimta Labs ; Aizant therapeutics ; Incozen Therapeutics ; Med-Himalayas ; Sai advantum ; Laxai Avanti ; Mithros chemicals ; Imptech Scientific 
Title: $1,000 genome
Content:  U.S. company is announcing... that it has achieved that milestone." In January 2014, Illumina launched its HiSeq X Ten Sequencer, claiming to have produced the first $1,000 genome at 30× coverage. Some researchers hailed the HiSeq X Ten's release as a milestone – Michael Schatz of Cold Spring Harbor Laboratory said that "it is a major human accomplishment on par with the development of the telescope or the microprocessor". However, critics pointed out that the $10 million upfront investment required to purchase the system would deter customers. Furthermore, the $1,000 genome cost calculation left out overheads, such as the cost of powering the machine. In September 2015, Veritas Genetics (co-founded by George Church) announced $1,000 full-genome sequencing including interpretation for participants in the 
Title: Hamilton O. Smith
Content:  role in the sequencing of many of the early genomes at The Institute for Genomic Research, and in the assembly of the human genome at Celera Genomics, which he joined when it was founded in 1998. More recently, he has directed a team at the J. Craig Venter Institute that works towards creating a partially synthetic bacterium, Mycoplasma laboratorium. In 2003 the same group synthetically assembled the genome of a virus, Phi X 174 bacteriophage. Currently, Smith is scientific director of privately held Synthetic Genomics, which was founded in 2005 by Craig Venter to continue this work. Currently, Synthetic Genomics is working to produce biofuels on an industrial-scale using recombinant algae and other microorganisms.
Title: Galapagos NV
Content:  Galapagos Genomics NV was founded in 1999 as a joint venture between Crucell and Tibotec. The company later changed its name to Galapagos NV and completed its initial public offering on Euronext Amsterdam and Euronext Brussels in May 2005. The company uses a technological platform for its research, which is based on adenoviruses to introduce human gene sequences into a wide variety of human cell lines to knock-in or knock-down specific proteins. In 2019, Gilead Sciences and Galapagos entered into transformative research and development collaboration. Gilead and Galapagos have also agreed to amend certain terms around the development and commercialization of filgotinib.

Question: Verify the following claims with "True" or "False": The company that produces the Genome also makes the ALV X-1.
Answer: False